Drug Screening Using a Library of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Disease Specific Patterns of Cardiotoxicity

Running title: Liang et al.; Disease-specific hiPSC library for drug screening

Ping Liang, PhD1,2,3*; Feng Lan, PhD1,2,3*; Andrew S. Lee, BS1,2,3*; Tingyu Gong, PhD1,4; Veronica Sanchez-Freire, PhD1,2,3; Yongming Wang, PhD1,2,3; Sebastian Diecke, PhD1,2,3; Karim Sallam, MD1,3; Joshua W. Knowles, MD, PhD1,3; Paul J. Wang, MD1,3; Patricia K. Nguyen, MD1,3; Donald M. Bers, PhD5; Robert C. Robbins, MD3,4; Joseph C. Wu, MD, PhD1,2,3

1Dept of Medicine, Division of Cardiology; 2Institute for Stem Cell Biology and Regenerative Medicine; 4Stanford Cardiovascular Institute; 4Dept of Cardiothoracic Surgery; Stanford University School of Medicine, Stanford, CA; 5Dept of Pharmacology, University of California (Davis) School of Medicine, Davis, CA

*Contributed equally

Address for Correspondence:
Joseph C. Wu, MD, PhD
Stanford University School of Medicine
Lorry I. Lokey Stem Cell Research Building
265 Campus Drive, Rm G1120
Stanford, CA 94305-5111
Tel: 650-736-2246
Fax: 650-736-0234
E-mail: joewu@stanford.edu

Journal Subject Code: Basic science research:[132] Arrhythmias - basic studies
Abstract:

Background—Cardiotoxicity is a leading cause for drug attrition during pharmaceutical development and has resulted in numerous preventable patient deaths. Incidents of adverse cardiac drug reactions are more common in patients with pre-existing heart disease than the general population. Here we generated a library of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from patients with various hereditary cardiac disorders to model differences in cardiac drug toxicity susceptibility for patients of different genetic backgrounds.

Methods and Results—Action potential duration (APD) and drug-induced arrhythmia were measured at the single cell level in hiPSC-CMs derived from healthy subjects and patients with hereditary long QT syndrome (LQT), familial hypertrophic cardiomyopathy (HCM), and familial dilated cardiomyopathy (DCM). Disease phenotypes were verified in LQT, HCM, and DCM iPSC-CMs by immunostaining and single cell patch clamp. Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and the human ether-a-go-go-related gene (hERG) expressing human embryonic kidney (HEK293) cells were used as controls. Single cell PCR confirmed expression of all cardiac ion channels in patient-specific hiPSC-CMs as well as hESC-CMs, but not in HEK293 cells. Disease-specific hiPSC-CMs demonstrated increased susceptibility to known cardiotoxic drugs as measured by APD and quantification of drug-induced arrhythmias such as early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs).

Conclusions—We have recapitulated drug-induced cardiotoxicity profiles for healthy subjects, LQT, HCM, and DCM patients at the single cell level for the first time. Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than standard hERG test or healthy control hiPSC-CM/hESC-CM screening assays.

Key words: stem cell, cardiotoxicity
Introduction

Cardiac toxicity is a leading cause for drug attrition during the clinical development of pharmaceutical products. Of particular concern is the potential of new chemical entities (NCEs) to induce prolongation of the QT interval, a condition known to cause torsades de pointes (TdP), a rapid polymorphic ventricular tachyarrhythmia that can lead to sudden cardiac death. To minimize cardiac risks associated with drug development, both the pharmaceutical industry and U.S. Food and Drug Administration (FDA) have mandated in vitro cardiotoxicity screening early in NCE development. In spite of such guidelines, drug-induced TdP has resulted in numerous preventable patient deaths and the costly withdrawal of associated pharmacological products from the market.

A central reason for the high rates of adverse cardiac drug reactions observed in patients is the limited capacity of preclinical screening assays to detect cardiotoxicity. Current in vitro toxicity screens rely on the artificial expression of single cardiac ion channels in genetically transformed cell lines such as Chinese hamster ovary (CHO) or human embryonic kidney (HEK) cells, which do not accurately model pertinent genetic, cellular, or biochemical characteristics of the human heart. The use of CHO and HEK cells to assess cardiotoxicity is impaired by genetic aberrations accumulated in these cells and the failure of ectopically expressed channels to accurately model the same channels found in human cardiomyocytes (CMs). In addition, blockade of single ion channels alone has proven to be an imperfect measure of QT prolongation as CM electrophysiology is regulated by the concurrent activity of multiple ion channels. Consequently, screening of drugs that block single ion channels alone as with CHO or HEK cells can produce false negatives (i.e., Alfuzosin) and false positives (i.e., Verapamil), leading to the market release of potentially lethal drugs and the attrition of valuable drugs, respectively.
To improve the accuracy of toxicity screening, preclinical drug tests ideally would be conducted on adult human CMs. Unfortunately, this has not been feasible in early stage drug discovery due to the difficulties in obtaining cardiac tissue from patients and the inability to propagate these cells in culture. The recent derivation of human CMs from embryonic stem cells (hESC-CMs) and induced pluripotent stem cells (hiPSC-CMs) represents a possible method to circumvent these hurdles, because both hESC-CMs and hiPSC-CMs possess many of the same electrical characteristics as primary human CMs and can be generated in unlimited quantities from pluripotent cell sources.\textsuperscript{16,17}

The use of patient-specific hiPSC-CMs offers a unique opportunity to transform drug toxicity screening because the majority of individuals who experience adverse cardiac drug responses belong to specific high-risk demographics. For example, episodes of TdP and sudden cardiac death related to the gastromotility agent cisapride in the mid-1990s were largely absent from the general population and limited to patients with pre-existing heart conditions such as long QT syndrome and heart failure\textsuperscript{19}. Several recent reports have detailed the derivation of hiPSC-CMs from patients with long QT syndrome (LQT), as well as other hereditary cardiac disorders such as LEOPARD syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), familial hypertrophic cardiomyopathy (HCM), and familial dilated cardiomyopathy (DCM)\textsuperscript{20-26}. However, these reports did not examine whether such patient-specific cells accurately model torsadogenic responses to cardiototoxic drugs. In this study, we therefore generated a disease-specific hiPSC-CM library from patients with common hereditary cardiac disorders and tested the capacity of this panel to be used as a surrogate \textit{in vitro} model for prediction of cardiac drug toxicity in patient groups at high risk for drug-induced TdP.
Methods

Culture and maintenance of undifferentiated hESCs and hiPSCs

The H9 hESC line was obtained from WiCell (Madison, WI). Characteristics of hiPSC lines including mutations are summarized in Supplemental Table 1. hESCs and hiPSCs derived from healthy controls, or patients diagnosed with LQT syndrome, HCM, or DCM were maintained in feeder-free mTeSR1 medium (STEMCELL Technologies, Vancouver, Canada) on Matrigel-coated (BD Bioscience, San Jose, CA) plates at 37°C with 5% (vol/vol) CO₂.

Differentiation of hESCs and hiPSCs into cardiac lineages

hESC and hiPSC lines were differentiated via embryoid body (EB) formation using a previously described protocol ²⁷. Briefly, on day 0 of differentiation, hESC and hiPSC colonies were dissociated with Accutase (Sigma) into small clumps of 10-20 cells. Cells were resuspended in 2 ml basic media containing StemPro34 (Invitrogen), 2 mM glutamine (Invitrogen), 0.4 mM monothioglycerol (Sigma), 50 μg/ml ascorbic acid (Sigma), and 0.5 ng/ml BMP4 (R&D Systems, Minneapolis, MN) to form EBs. For the first 1-4 days of cardiac differentiation, cells were treated with 10 ng/ml BMP4, 5 ng/ml human bFGF (R&D Systems), and 3 ng/ml activin A (R&D Systems) added to the basic media. On days 4-8, EBs were re-fed with basic media containing human 50 ng/ml DKK1 (R&D Systems) and 10 ng/ml human VEGF (R&D Systems). From day 8 onwards, cells were treated with basic media containing 5 ng/ml human bFGF and 10 ng/ml human VEGF. Beating EBs were dissociated into single beating hiPSC-CMs for patch clamping and drug treatment assays.

Assessment of disease phenotype by measurement of cell size and myofilament disarray

The in vitro disease phenotypes for diseased hiPSC-CMs was assessed by immunofluorescence staining for cardiac disease markers, quantification of disorganized saromeric content, and
assessment of cell size. Beating hiPSC-CMs were plated on gelatin-coated dishes. After three days in culture, beating hiPSC-CMs were trypsinized and re-plated at low density on gelatin-coated chamber slides (Nalgene Nunc International, Rochester, NY). Cells were fixed with 4% paraformaldehyde (Sigma), permeabilized in 0.3% Triton (Sigma), blocked using 5% BSA, and stained with primary antibody overnight at 4°C. Stained cells were washed three times with PBS, and then incubated with secondary antibody for 1 h at 25°C. Sarcomeric disarray and cell size of normal and diseased hiPSC-CMs were quantified using the ImageJ software package (National Institutes of Health, Bethesda, MD). Cells with disorganized sarcomeres were defined as having greater than 25% cell area of punctate troponin T distribution without striations, suggesting disorganized myofilament structure.

**Compound solutions used in drug screening assays.**

All drugs used in this study were purchased from Sigma-Aldrich. Cisapride, nicorandil, and alfuzosin were dissolved in DMSO, while verapamil was dissolved in H2O. Drug compound solution was prepared as a 10 mM stock in a glass vial. Stock solution was mixed vigorously for 10 min at room temperature. For testing, pharmaceutical compounds were diluted in a glass vial using external solution (137 mM NaCl, 4 mM KCl, 1 mM MgCl₂, 10 mM glucose, 1.8 mM CaCl₂, and 10 mM HEPES). Dilutions were prepared within 30 min of treatment. Equal amounts of DMSO (0.1%) were present at final dilution and used as vehicle controls.

**Electrophysiologic recordings of HEK293 cells and hESC-CMs/hiPSC-CMs**

hERG tail currents were recorded from hERG expressing HEK293 cells with the use of standard patch-clamp techniques, as previously reported. To record action potentials, contracting embryoid bodies (EBs) were mechanically isolated, enzymatically dispersed into single cells, and attached to 0.1% gelatin-coated glass coverslips. Single beating cardiomyocytes were
subjected to whole-cell patch-clamp at 36-37°C using an EPC-10 patch-clamp amplifier (HEKA, Lambrecht, Germany) attached to a RC-26C recording chamber (Warner) and mounted on to the stage of an inverted microscope (Nikon, Tokyo, Japan). Data were acquired using PatchMaster software (HEKA, Germany) and digitized at 1.0 kHz. Current-clamp recordings were conducted in Tyrodes solution. Significant APD$_{90}$ prolongation is defined in this study as >10% change in APD$_{90}$ at the indicated concentration $^{11}$. 

**Statistical analysis**

Statistical significance was determined by paired or unpaired Student’s t test (two-tail) for comparison between two groups. For statistical comparison between more than two groups, one-way ANOVA followed by the Dunnett test was employed. *P < 0.05 was considered statistically significant, ** indicates P < 0.01, and *** indicates P < 0.001.

A more detailed description of the methods used in this study can be found in the **Supplemental Methods** section of the manuscript.

**Results**

**Patient recruitment and confirmation of disease-specific mutations**

Protocols for this study were approved by the Stanford University Human Subjects Research Institutional Review Board, and written consent was obtained from all study participants. Dermal fibroblasts were isolated from three distinct family cohorts of patients diagnosed at Stanford Hospital with hereditary mutations for long QT syndrome (LQT), hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM) (n=3 patients per cohort; **Supplemental Figure 1a, Supplemental Table 1**) as previously reported $^{23,26}$. Nucleotide sequence analysis confirmed the presence of known causal disease mutations for each respective patient cohort, specifically the
G269S missense mutation in KCNQ1 for the LQT cohort, R663H in MYH7 for the HCM cohort, and R173W in TNNT2 for the DCM cohort (Supplemental Figure 1b-d). Screening of hESCs (WA09 line) and family-matched control hiPSCs did not reveal any known mutations related to LQT, HCM, or DCM (Supplemental Table 2). To ensure genetic diversity among the control group, skin biopsies were obtained from at least one healthy individual from each of the LQT, HCM, and DCM family cohorts to serve as a disease-free control.

**Generation of patient-specific iPSCs from dermal fibroblasts**

Disease-specific hiPSCs were generated from fibroblasts derived from LQT, HCM, and DCM patient cohorts through lentiviral infection with the reprogramming factors OCT4, SOX2, MYC, and KLF4. Control hiPSCs were derived from age-matched healthy subjects from the same diseased family cohorts. A minimum of 3 distinct lines was generated per patient. Pluripotency was confirmed through immunofluorescence staining for the ESC markers TRA-1-60, TRA-1-81, and SSEA-4 (Figure 1a). Silencing of reprogramming transgenes was determined by qPCR for total and endogenous expression of the pluripotency transcription factors OCT4, SOX2, MYC, and KLF4 (Supplemental Figure 2). Embryoid body (EB) and teratoma formation assays demonstrated capacity of all lines to generate cellular derivatives of all three germ layers *in vitro* and *in vivo* (Supplemental Figure 3).

**Differentiation of patient-specific hiPSCs into cardiomyocytes**

Patient-specific hiPSCs were differentiated into cardiomyocytes using standard 3D EB differentiation protocols as previously described. Differentiated EBs exhibited spontaneously contracting foci as early as ten days following initiation of cardiac differentiation (Supplemental Video 1). Dissociation of beating colonies into single cardiomyocytes demonstrated that single hESC-CMs and hiPSC-CMs maintained spontaneous contraction and positive staining for
distinct myocyte markers (Figure 1b-c) and spontaneous contraction (Supplemental Video 2). FACS analysis for Troponin T at 30 days post-differentiation revealed beating cultures contained cardiomyocyte purities of greater than 90% (Figure 1d). No significant discrepancies in efficiency of cardiac differentiation were observed among disease-specific hiPSC lines, control hiPSC lines, and control hESC lines (Supplemental Figure 4).

**Comparison of in vitro disease phenotypes for patient-specific hiPSC-CMs**

Following cardiac differentiation, patient-specific hiPSC-CMs from LQT, HCM, and DCM family cohorts were dissociated into single beating cells and characterized in vitro for expression of cardiac disease phenotypes. To ensure genetic diversity among disease-free hiPSC-CMs, patient-specific control hiPSC-CM lines were derived from separate healthy individuals belonging to the LQT, HCM, and DCM family cohorts. hESC-CMs (WA09 line) were also used as a disease-free control. Immunofluorescence staining of patient-specific hiPSC-CMs revealed immediate phenotypic differences in cells derived from patients with hereditary HCM and DCM mutations as compared to control hESC-CMs and control hiPSC-CMs. Specifically, hypertrophic hiPSC-CMs exhibited several features of HCM including cellular enlargement and sarcomeric disorganization (Figure 2a-c, Supplemental Figure 5). DCM hiPSC-CMs also exhibited disorganized sarcomeric staining patterns suggestive of myofibril disarray as previously reported 23. By comparison, control hESC-CMs, control hiPSC-CMs, and LQT hiPSC-CMs exhibited normal cell sizes and minimal sarcomeric disorganization (Figure 2a-c).

In addition to cellular hypertrophy and disorganization of sarcomeric content, HCM hiPSC-CMs also demonstrated disease characteristics associated with HCM such as elevated expression of atrial natriuretic factor (ANF) and nuclear translocation of nuclear factor of activated T-cells (NFAT) (Figure 2d-e). By comparison, control hESC-CMs, control hiPSC-
CMs, LQT hiPSC-CMs, and DCM hiPSC-CMs exhibited lower levels of ANF expression and nuclear NFAT translocation (Figure 2f-g). Hypertrophic transcription factors activated by nuclear translocation of NFAT such as GATA4 and MEF2C were also found to be elevated in HCM hiPSC-CMs as compared to other patient-specific lines (Figure 2h). Taken together, these results indicate that cohorts of disease-specific hiPSC-CMs recapitulate distinct pathologic phenotypes associated with clinical presentations of LQT, HCM, and DCM, respectively.

**Gene expression profiles of cardiac ion channels in hESC- and hiPSC-CMs**

The use of pluripotent stem cell-derived cardiomyocytes to accurately model drug-induced cardiotoxicity *in vitro* is predicated on the expression of the full range of adult cardiac ion channels naturally found in the human heart. However, to date only a fraction of the ion channels endogenously expressed in adult cardiomyocytes have been verified to be present in hESC-CMs and hiPSC-CMs. To evaluate the potential of control and disease-specific hiPSC-CMs as well as hESC-CMs to be used as surrogate models for adult cardiomyocytes, total RNA was isolated from beating cultures of hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs. RNA isolated from adult cardiac left ventricular (LV) tissue and HEK293 cells was used as positive and negative controls, respectively. Quantitative PCR demonstrated that hESC-CMs, control hiPSC-CMs, and disease-specific hiPSC-CMs expressed all cardiac ion channels found in adult LV cardiac tissue using a panel of 14 ion channel-related transcripts, including SCN5A, KCND3, CACNA1C, KCNH2, KCNQ1, KCNA5, HCN2, HCN4, KCNJ2, KCNJ3, KCNJ5, KCNJ11, KCNE1, and KChIP2 (Supplemental Table 3). By comparison, HEK293 cells overexpressing the hERG channel (hERG-HEK293) used in the hERG assay were only found to express KCNH2 (Figure 3). These findings indicate that unlike the hERG assay, hESC-CMs and hiPSC-CMs have the potential to
model electrophysiological responses to pharmaceutical compounds that affect multiple cardiac ion channels.

**Electrophysiological characterization of control and disease-specific iPSC-CMs**

To establish electrophysiological baselines of control and disease-specific hiPSC-CMs, spontaneous action potentials were recorded from single beating cardiomyocytes derived from H9 hESCs and from control, LQT, HCM, and DCM hiPSCs. Nodal-, atrial-, and ventricular-like waveforms were detected in CMs from all lines as determined by the morphology of the action potentials generated and by the APD$_{90}$/APD$_{50}$ ratio (Figure 4a, Supplemental Table 4). No significant differences in beating rate, maximum diastolic potential (MDP), overshoot, action potential amplitude (APA), and maximal rate of depolarization (V$_{max}$) were detected between hESC-CMs and control, LQT, HCM, and DCM hiPSC-CMs (Supplemental Figure 6). However, LQT hiPSC-CMs exhibited significantly longer action potential durations at 50%, 70%, and 90% repolarization (APD$_{50}$, APD$_{70}$, APD$_{90}$) as compared to control lines and other patient-specific lines (Figure 4c, Supplemental Table 4). Control hiPSC-CMs derived from LQT, HCM, and DCM family cohorts did not exhibit significant differences in electrophysiological baselines, suggesting that healthy hiPSC-CMs derived from different genetic backgrounds are phenotypically similar (Supplemental Figure 7a-c).

Studies modeling disease progression of LQT using patient-specific hiPSC-CMs have demonstrated recapitulation of arrhythmic phenotypes *in vitro* $^{20,21,32}$. We therefore profiled incidence of arrhythmia in control and disease-specific hiPSC-CMs to determine normal electrophysiological baselines for our platform. To ensure analyses were standardized between different cell lines, we only profiled cell subpopulations with ventricular-like waveforms. Significantly, both LQT and HCM hiPSC-CMs exhibited a high incidence of arrhythmia.
including early afterdepolarizations (EADs) in LQT hiPSC-CMs (33.3 ± 9.7%) and delayed afterdepolarizations (DADs) in HCM hiPSC-CMs (40.3 ± 7.5%) (Figure 4d-g). By contrast, hESC-CMs, control hiPSC-CMs, and DCM hiPSC-CMs exhibited very low frequencies of irregular electrophysiological waveforms. Comparison of control hiPSC-CM lines revealed no significant differences between control hiPSC-CMs derived from healthy individuals from LQT, HCM, and DCM family cohorts (Supplemental Figure 7d).

**Comparison of hiPSC-CM and hERG assay for detection of QT prolongation**

Preclinical drug toxicity screening using hERG blockade has been shown to incorrectly predict cardiotoxicity for a number of pharmaceutical compounds. These include false positives such as verapamil that are not cardiotoxic but block the hERG channel, as well as false negatives such as alfuzosin, which do not bind hERG but elicit QT prolongation through interactions with other ion channels. To determine whether our platform is superior to hERG assay for detection of cardiotoxicity, we screened both verapamil and alfuzosin on commercial HEK293 cells stably expressing hERG (hERG-HEK293) and control hiPSC-CMs from our patient library.

Cardiotoxic readout of the hERG-HEK293 assay was evaluated through calculation of the half maximal inhibitory concentration (IC₅₀) to inhibit the hERG peak tail current, a surrogate measure for QT prolongation. By comparison, cardiotoxic readout of drug-treated hiPSC-CMs was determined through assessment of the (IC₅₀) to significantly prolong the APD₉₀, which is a more direct and physiologically relevant measurement of the QT interval.

Patch clamp recordings in hERG-HEK293 cells demonstrated verapamil inhibits hERG tail current in a dose-dependent manner at a low concentration, suggesting high potential for cardiotoxicity (IC₅₀ = 0.19 ± 0.05 μM; Figure 5a-b, Supplemental Table 5), whereas vehicle (0.1% DMSO) showed no effect on hERG tail current (Supplemental Figure 8).
comparison, treatment of hESC-CMs and hiPSC-CMs with verapamil demonstrated both dose-dependent shortening of the Phase 2 APD due to L-type Ca^{2+} channel blockade and dose-dependent prolongation of the Phase 3 APD due to hERG channel blockade (Figure 5c-d, Supplemental Figure 9a, Supplemental Table 6). As a result, significant APD_{90} prolongation in hESC-CMs and hiPSC-CMs was not observed at physiological concentrations of the drug (Figure 5c-d, Supplemental Figure 9a, Supplemental Table 6).

We next treated hERG-HEK293 cells with alfuzosin, a drug that can increase sodium channel current that is known to cause QT prolongation in patients\(^\text{14}\). Alfuzosin treatment demonstrated little potential to block hERG (IC\(_{50}\) = 11.3 ± 0.7 \mu M; Figure 5e-f, Supplemental Table 5).

However, when tested on control hESC-CMs and hiPSC-CMs, alfuzosin was found to produce a significantly dose-dependent prolongation of the APD_{90} from concentrations as low as 1 \mu M (hESC-CM IC\(_{50}\) = 2.9 ± 1.1 \mu M, hiPSC-CM IC\(_{50}\) = 2.1 ± 0.9 \mu M; Figure 5g-h, Supplemental Figure 9b, Supplemental Table 6). Vehicle alone (0.1% DMSO) had no effect on AP waveforms (Supplemental Figure 10). Taken together, these findings indicate that hESC-CMs and hiPSC-CMs are more accurate predictors of drug-induced cardiotoxicity than hERG-HEK293 cells.

**Evaluation of drug-induced cardiotoxicity in control and disease-specific hiPSC-CMs**

Several recent studies have demonstrated proof-of-principle for hESC-CMs and hiPSC-CMs to model pharmaceutical responses of various drugs\(^\text{22, 30, 33-36}\). However, the majority of these studies have been conducted using hESCs and hiPSCs derived from subjects without known risk for cardiac disorders. These cells therefore could not recapitulate the clinical experience of individuals at high risk for adverse cardiac drug reactions. As the majority of cardiotoxic incidents occur in patients with pre-existing heart conditions and not healthy individuals, we
aimed to test whether disease-specific hiPSC-CMs have higher susceptibilities to cardiotoxicity as compared to control hESC-CMs and hiPSC-CMs. Diseased hiPSC-CMs derived from individuals with LQT, HCM, and DCM were treated in parallel with control hESC-CMs and hiPSC-CMs with a panel of drugs known to interact with different cardiac ion channels (Supplemental Table 7). Cardiotoxic readouts for each of these compounds were measured by its potential to induce arrhythmia or affect the APD in single hiPSC-CMs.

Distinct control and disease-specific hiPSC-CMs were first screened for toxicity to cisapride, a potent hERG blocking drug removed from market in 2000 (Supplemental Figure 11a-c, Supplemental Table 5) 19. Control, LQT, HCM, and DCM hiPSC-CMs were treated with a range of doses (1 nM – 300 nM), and cardiotoxic responses were evaluated by whole-cell patch clamp. Cisapride was observed to elicit EADs at different concentrations for each disease-specific cell line (Figure 6a-b). LQT and HCM hiPSC-CMs, which exhibited EADs and DADs at electrophysiological baselines, were found to have increased susceptibility to cisapride-induced arrhythmia. While control and DCM hiPSC-CMs largely demonstrated EADs at concentrations of cisapride ≥ 300 nM, LQT and HCM hiPSC-CMs exhibited cisapride-induced EADs at concentrations as low as 30 nM (Figure 6b-c, Supplemental Table 6). The arrhythmic waveforms elicited by cisapride in LQT and HCM lines were also more punctuated than in control or DCM hiPSC-CMs. In addition to arrhythmia, LQT and HCM hiPSC-CMs were also found to have more adverse reactions to cisapride-induced APD prolongation than DCM hiPSC-CMs and control hiPSC-CMs (Figure 6d-e, Supplemental Table 6). Control hiPSC-CMs derived from healthy individuals within the LQT, HCM, and DCM family cohorts exhibited similar patterns of cisapride-induced cardiotoxicity (Supplemental Figure 12a-b). These results indicate that as compared to cells derived from control or DCM patients, hiPSC-CMs containing...
LQT or HCM mutations are more sensitive to cardiotoxicity caused by pharmacological blockade of hERG.

We next evaluated the potential of the K\(^+\) ATP channel opener nicorandil to elicit differential drug responses between control, LQT, HCM, and DCM hiPSC-CMs. Previous studies have shown nicorandil shortens the QT interval through enhancement of K\(^+\) outflux and can ameliorate LQT-induced arrhythmias at moderate doses. Treatment of our LQT hiPSC-CMs at low doses of nicorandil supported these results, as 100 nM was found to both normalize APD prolongation and abolish spontaneously occurring EADs (7 out of 10 cells, 3 patient lines) (Figure 7a). Several recent studies have also reported induction of arrhythmia and ventricular fibrillation in patients receiving high doses of nicorandil due to excessive shortening of the QT interval. We therefore aimed to assess whether patient-specific hiPSC-CMs could recapitulate short QT cardiotoxicity. Interestingly, LQT hiPSC-CMs exhibited heightened sensitivity to nicorandil-induced cardiotoxicity at high doses, including exhibition of proarrhythmias (7 out of 9 cells, 3 patient lines) (Figure 7a). These abnormalities were not observed in control cells (Figure 7b). Moreover, LQT and DCM hiPSC-CMs demonstrated extreme QT shortening induced by nicorandil (IC\(_{50}\) of APD\(_{90}\) shortening for LQT = 3.44 ± 1.11 μM, IC\(_{50}\) of APD\(_{90}\) shortening for DCM = 8.32 ± 1.35 μM; Figure 7c-e, Supplemental Table 6). By comparison, control and HCM hiPSC-CMs were not found to exhibit excessive QT shortening as induced by nicorandil (IC\(_{50}\) of APD\(_{90}\) shortening for control = 13.44 ± 2.1 μM, IC\(_{50}\) of APD\(_{90}\) shortening for HCM = 11.45 ± 2.30 μM; Figure 7c-e, Supplemental Table 6). Control hiPSC-CMs derived from healthy individuals within the LQT, HCM, and DCM family cohorts exhibited similar response patterns to nicorandil-induced cardiotoxicity (Supplemental Figure 12c-d). Taken together, these findings suggest disease-
specific hiPSC-CMs are characterized by distinct pharmacological responses to drug-induced cardiotoxicities, and that these differences may underlie the sensitivities of specific patient populations to adverse cardiac drug reactions.

**Discussion**

Drug-induced cardiac toxicity is a major risk in pharmaceutical development. The US Department of Health and Human Services estimates that nearly 1 million patients suffer from adverse drug reactions each year, of which drug-induced arrhythmia is the leading cause. As a result, both the FDA and pharmaceutical industry have instituted mandatory preclinical drug screening guidelines to detect potential cardiac toxicity before market release. Current preclinical cardiotoxicity assays are based upon the International Conference on Harmonization (ICH) Supplement S7B, and focus on screening for compounds that prolong the QT interval through blockade of the hERG potassium channel. The hERG assay is known to be an inaccurate predictor of cardiac toxicity, however, and regularly results in false negative and false positive readouts. Use of animal hearts as surrogate models for the human heart are also limited because murine, canine, and rabbit cardiomyocytes are characterized by different electrophysiological properties and fail to respond to certain drugs in a similar manner to humans. The generation of cardiomyocytes from hESCs and hiPSCs offers a potential method to circumvent the inaccuracies of hERG and animal models by allowing for drug screening to be performed directly on human heart cells *in vitro* for the first time.

Derivation of patient-specific hiPSCs presents the unprecedented opportunity to improve our understanding of hereditary cardiac disorders through “disease in a dish” modeling (**Supplemental Figure 13**). Recent studies have demonstrated potential of hiPSCs to recapitulate
disease phenotypes of genetic cardiac diseases such as dilated cardiomyopathy, long QT, CPVT, and LEOPARD syndrome. The capacity for hiPSC-based disease modeling has important ramifications for drug toxicity screening as the majority of adverse cardiac drug reactions occur in patients with hereditary cardiac disease. Patients with LQT, HCM, and DCM, are particularly sensitive to cardiotoxic drugs and are vulnerable to fatal arrhythmias. To test whether hiPSC-CMs could model the increased susceptibility of genetic cardiac disorders to drug-induced cardiotoxicity, we characterized and screened a library of hiPSC-CMs derived from patients with LQT, HCM, and DCM for a panel of drugs known to affect cardiac ion channels.

Our findings have several important implications for the use of patient specific hiPSC-CMs to detect drug-induced cardiotoxicity. First, we demonstrate the patient-specific hiPSC-CMs in our cell library exhibit distinct in vitro phenotypes associated with the control, LQT, HCM, and DCM patients from which they were derived. Second, we profiled control and disease-specific hiPSC-CMs for expression of a full panel of cardiac ion channels known to be associated with drug-induced cardiotoxicity. While previous reports have demonstrated proof-of-principle for hESC-CMs and hiPSC-CMs to model Na\(^+\), Ca\(^{2+}\), and K\(^+\) ionic currents, these studies have only assessed gene expression for a subset of cardiac ion channels. Furthermore, the analyses in these reports are largely limited to 1-2 cell lines, which are not representative of the genetic diversity embodied by the general population. In our study, we have profiled gene expression for all major cardiac ion channels for a library of hiPSC-CMs derived from 12 individuals of different genetic backgrounds. We demonstrate that regardless of presence or absence of in vitro disease phenotype, the patient-specific hiPSC-CMs assessed in our study express all major cardiac ion channels at similar levels to hESC-CMs. As a result, in head-to-head comparisons conducted within our study, hiPSC-CMs modeled cardiotoxicities more...
accurately than commercial hERG cell lines. To date, this is the first report we know of to
directly compare hiPSC-CM and hERG assays for detection of drug-induced cardiotoxicity at the
single cell level.

Screening of our patient cell library also demonstrated disease-specific hiPSC-CMs are
more susceptible to drug-induced cardiac toxicity than control hiPSC-CMs as assessed by
measurement of the QT interval prolongation and induction of arrhythmia. Diseases
characterized by an elevated baseline of arrhythmia such as LQT and HCM exhibited a particular
propensity for exhibition of drug-induced EADs by hERG blockade with cisapride. The high
frequency of baseline arrhythmias and electrophysiological abnormalities observed in LQT and
HCM hiPSC-CMs may be explained by imbalances in ion channel homeostasis caused by
mutations in KCNQ1 and MYH7, respectively. Previous LQT hiPSC-CM modeling studies have
observed baseline EADs and attributed these to sensitization of late-membrane inward currents
\(^{20}\). For HCM, several studies have demonstrated that increased intracellular calcium retention by
MYH7 mutations can lead to presentation of DADs \(^{44}\).

Interestingly, we observed a cut-off within the therapeutic window of cisapride (3 nM) at
which LQT and HCM hiPSC-CMs exhibited significant QT prolongation, but control hiPSC-
CMs did not. In addition, we also observed a second cut-off (30 nM) at which cisapride was
found to induce EADs in LQT and HCM hiPSC-CMs, but not in control or DCM cells. The
heightened sensitivity of LQT and HCM hiPSC-CMs to cisapride toxicity are likely caused by
drug-induced exacerbation of the baseline arrhythmias observed in both of these cell cohorts as
shown in previous studies \(^{24}\). Control and DCM hiPSC-CMs, which did not exhibit baseline
arrhythmia or APD prolongation, required higher doses of cisapride for exhibition of drug-
duced cardiotoxicity at the single cell level. These results replicate epidemiological findings in
which the majority of patients found to undergo adverse drug reactions to cisapride exhibited pre-existing QT prolongation and arrhythmia.19

Our findings further indicate that hiPSC-CMs recapitulate patient-specific susceptibilities to drug-induced toxicities other than blockade of hERG. Nicorandil is a K⁺ ATP channel opener that shortens APD by increasing in K⁺ outflux. While experimental models have shown K⁺ ATP channel openers can ameliorate LQT at low to moderate doses, the use of nicorandil has also been associated with induction of arrhythmia and ventricular fibrillation in patients with ischemic dilated cardiomyopathy.38,39 High doses of nicorandil have been shown to induce arrhythmia in hiPSC-CM and animal models of LQT through excessive shortening of the QT interval.38,45 In DCM, several studies have demonstrated that depletion of cellular ATP reserves impedes proper regulation of K⁺ATP channel opening, resulting in arrhythmias following potassium outflow.39 Our findings support these results as both DCM and LQT hiPSC-CMs were found to exhibit drug-induced proarrhythmias when treated with doses of nicorandil > 10 μM. By comparison, treatment of HCM or control hiPSC-CMs with the same dosage of nicorandil was not observed to induce arrhythmia.

In summary, our results indicate that disease-specific hiPSC-CMs can recapitulate clinical susceptibilities of high-risk populations to drug-induced cardiotoxicities, and that the use of a patient-specific hiPSC-CM library to detect cardiotoxicity may be superior to utilization of hESC-CMs or hERG assay alone. However, it is important to note there are several limitations to our approach. These include the developmental immaturity of iPSC-CMs as compared to adult cardiomyocytes, and the inability of single cells to model arrhythmic triggers at the tissue level such as interstitial fibrosis and re-entry.20,22,26 Furthermore it is critical to recognize the iPSC-CM libraries used in this study are not equivalent substitutes for adult cardiomyocytes found in
our patient cohorts. Rather, our approach is an in vitro method to model the effects of disease-specific differences in adverse drug response between different patient populations. We believe the future use of a diverse patient hiPSC-CM library in future drug toxicity screens will contribute toward the stratification of clinical trials by refinement of thresholds for cardiotoxicity as well as identification of patient populations at high-risk for cardiac toxicity.

**Acknowledgments:** We thank Ziyan Zhang for preparing high-resolution figures. We gratefully acknowledge funding support from NIH New Innovator Award DP2OD004437, R01 HL113006, CIRM RB3-05129, Leducq Foundation 11CDV02, Burroughs Wellcome Foundation (JCW), Bio-X (ASL), and U01 HL099776 (RCR).

**Conflict of Interest Disclosures:** None.

**References:**


**Figure Legends:**

**Figure 1.** Characterization of disease-specific hiPSC lines and hiPSC-CMs from control, LQT, HCM, and DCM patients. (a) Representative immunostaining for a panel of pluripotent stem cell markers, including OCT4, SOX2, NANOG, TRA1-60, TRA1-81, and SSEA4 in H9 hESCs, control hiPSCs, LQT hiPSCs, HCM hiPSCs, and DCM hiPSCs. Scale bar, 50 μM. (b) Brightfield (BF) images of hiPSC-CMs generated from disease-specific cohorts and from H9 hESCs. Scale bar, 50 μM. (c) Immunostaining for the cardiac sarcomere markers α-ACTININ and TNNT2. Scale bar, 50 μM. (d) Flow cytometry analysis for the percentage of cells exhibiting positive TNNT2 staining. Isotype controls are shown in red, whereas stained hiPSC-CMs are shown in green.

**Figure 2.** *In vitro* assessment of disease phenotype recapitulation for control, LQT, HCM, and DCM hiPSC-CMs. (a) Representative immunostaining of single hiPSC-CMs for cardiac troponin T and F-actin demonstrating increased cellular size in HCM hiPSC-CMs, and increased fraction
of cells with disorganized sarcomeres in HCM and DCM hiPSC-CMs, compared with hESC-CMs, control hiPSC-CMs, and LQT hiPSC-CMs. White arrows indicate the disorganized sarcomeres in HCM and DCM hiPSC-CMs. Scale bar, 50 μM. (b) Quantification of cell size for hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (n=135-256, 3 lines per cohort). (c) Quantification of % cells with disorganized sarcomeres for hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (n=85-147, 3 lines per cohort). (d) Representative immunostaining of hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs reveals elevated ANF expression in HCM hiPSC-CMs as compared to other groups. White arrow indicates elevated ANF staining in HCM hiPSC-CMs. Scale bar, 50 μM. (e) Representative immunostaining of hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs and DCM hiPSC-CMs reveals nuclear translocation of NFATC4 in HCM hiPSC-CMs. White arrow indicates elevated staining for nuclear translocation of NFATC4 in HCM hiPSC-CMs. Scale bar, 50 μM. (f) Quantification of ANF expression for hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (n=43-75, 3 lines per cohort). (g) Percentage of cardiomyocytes exhibiting positive NFATC4 staining in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (n=76-115, 3 lines per cohort). (h) HCM-related gene expressions (GATA4, MEF2C, ANF, and TNNT2) in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs by quantitative PCR (qPCR) (n=3). * indicates P<0.05, as compared to control hiPSC-CMs.

**Figure 3.** Gene expression of cardiac ion channel transcripts in disease-specific hiPSC-CMs. Quantitative PCR results for expression of the primary 14 cardiac ion channel transcripts...
(SCN5A, KCND3, CACNA1C, KCNH2, KCNQ1, KCNA5, HCN2, HCN4, KCNJ2, KCNJ3, KCNJ5, KCNJ11, KCNE1, and KChIP2) responsible for the electrophysiological function in adult CMs. HEK-293, and hERG expressing HEK293 cells (hERG-HEK293) were used as negative controls, whereas adult LV tissue was used as a positive control (n=3, 2 lines per group).

**Figure 4.** Baseline AP characteristics of control, LQT, HCM, and DCM hiPSC-CMs. (a) Typical recordings of ventricular-, atrial-, and nodal-like action potentials from hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs. (b) Schematic diagram of a patch-clamp trace, showing how results were analyzed to calculate action potential duration at 50, 70, and 90% repolarization (APD50, APD70, and APD90, respectively). (c) APD50, APD70, and APD90 for each of the three myocyte subtypes in control, LQT, HCM, and DCM patient groups (n=70, 3 lines per cohort). (d) Representative recordings of ventricular-like action potentials from control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (n=70, 3 lines per cohort). Arrowheads show putative early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs). (e) Magnification of the underlined segment of the LQT AP tracing shows a representative EAD waveform at an expanded timescale. (f) Magnification of the underlined segment of the HCM AP tracing shows a representative DAD waveform at an expanded timescale. (g) Percentage of disease-specific cardiomyocytes displaying DADs and EADs, respectively (Control: n=128 cells, 3 control subject lines; LQT: n=90 cells, 3 patient lines; HCM: n=134 cells, 3 patient lines; DCM: n=70 cells, 3 lines). Dashed lines show 0 mV. *** indicates P<0.001.
Figure 5. Comparison of hERG blockade assay with hiPSC-CMs for detection of cardiotoxicity using verapamil and alfuzosin. (a) Representative tracings demonstrating the effect of verapamil on HEK293 hERG current at doses of 0, 0.01, 0.1, 0.3, 1, 10, and 100 μM (black, red, blue, purple, magenta, cyan, and green traces, respectively) (n=3). Dose-dependent hERG current inhibition was observed. (b) Dose-response relationship demonstrating steady-state inhibition of hERG by verapamil. IC50 was calculated by fitting a Hill function to the data constrained to 100% inhibition. IC50 for verapamil was 0.194 ± 0.05 μM (n=3 for each dose). (c) Representative traces of the effect of verapamil, a hERG and L-type Ca2+ channel blocker, on the control hiPSC-CM AP at doses of 0, 0.1, 1, 10, and 30 μM (black, red, blue, purple, and magenta traces, respectively) (n=8, 3 lines). Dose-dependent prolongation of the Phase III of the AP was observed, demonstrating blockade of the hERG channel. Dose-dependent shortening of the Phase II of the AP was also observed, indicating that AP prolongation induced by hERG blockade was offset by AP shortening caused by L-type Ca2+ channel inhibition. (d) Dose-response relationship showing the steady-state prolongation of hiPSC-CM APD90 by verapamil. IC50 was calculated by fitting a Hill function to the data, providing an IC50 value of verapamil at 5.18 ± 2.6 μM (n=8, 3 lines). (e) Representative tracings showing the effect of alfuzosin on HEK293 hERG current at doses of 0, 0.1, 1, 10, and 30 μM (black, red, blue, purple, and magenta traces, respectively) (n=3). Dose-dependent hERG current inhibition was observed. (f) Dose-response relationship showing the steady-state inhibition of hERG by alfuzosin. IC50 was calculated by fitting a Hill function to the data constrained to 100% inhibition. IC50 for alfuzosin was 11.34 ± 0.72 μM (n=3 for each dose). (g) Representative tracings showing the effect of alfuzosin on the control hiPSC-CM AP at doses of 0, 0.1, 0.3, 1, 3, and 10 μM (black, red, blue, purple, magenta, and cyan traces, respectively) (n=8, 3 lines). Dose-dependent AP prolongation was observed. (h) Dose-
response relationship showing the steady-state prolongation of hiPSC-CM APD$_{90}$ by alfuzosin. IC$_{50}$ was calculated by fitting a Hill function to the data, providing a IC$_{50}$ value of alfuzosin at 2.12 ± 0.93 μM (n=8, 3 lines). Dashed lines show 0 mV.

**Figure 6.** Differences in susceptibilities of disease-specific hiPSC-CMs to cisapride-induced cardiotoxicity. (a) Representative tracings showing dose-dependent effect of cisapride on the AP of control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs (Baseline: black, 1 nM: red, 3 nM: blue, 10 nM: purple, 30 nM: magenta, 100 nM: cyan, 300 nM: green). Arrowheads indicate cisapride-induced EADs. LQT hiPSC-CMs and HCM hiPSC-CMs were observed to exhibit cisapride-induced EADs at lower concentrations (30 nM) as compared to family matched control hiPSC-CMs and DCM hiPSC-CMs (300 nM) (n=10, 3 patient or control subject lines per cohort). (b) Aligned APs (in Panel a) showing the effects of cisapride on control, LQT, HCM, and DCM hiPSC-CMs (n=10, 3 patient or control subject lines per cohort). (c) Percentage of cardiomyocytes exhibiting cisapride-induced EADs in control, LQT, HCM, and DCM hiPSC-CMs at 30 nM, 100 nM, and 300 nM, respectively (n=6-9, 3 patient or control subject lines per cohort). Dashed lines show 0 mV. (d) Dose-response relationship showing the steady-state prolongation of APD$_{90}$ by cisapride for control, LQT, HCM, and DCM hiPSC-CMs. Data were fit by the Hill function (n=10, 3 patient or control subject lines per cohort). (e) IC$_{50}$ values of prolongation of APD$_{90}$ of cisapride for control, LQT, HCM, and DCM hiPSC-CMs (n=10, 3 patient or control subject lines per cohort). Dashed lines show 0 mV. * indicates P<0.05, ** indicates P<0.01.
induced by nicorandil. (a) Treatment of LQT hiPSC-CMs with 100 nM nicorandil normalizes the QT interval and abolishes baseline EADs. High doses (>10 μM) of nicorandil induce proarrhythmias. Upper panel: LQT hiPSC-CM AP baseline without EADs, 100 nM nicorandil is able to normalize the APD values. Treatment with 10 μM nicorandil induces arrhythmias (n=18, 3 patient lines per cohort). Bottom panel: LQT hiPSC-CM AP baseline with EADs (indicated by red arrows). 100 nM nicorandil can abolish baseline EADs. However, at treatment with 10 μM nicorandil, the QT interval is excessively shortened, resulting in nicorandil-induced arrhythmia as indicated by red arrows (n=9, 3 patient lines per cohort). (b) Treatment of control hiPSC-CMs with nicorandil. APD shortening is observed without arrhythmia or drug-induced toxicity at both 100 nM and 10 μM nicorandil (n=10, 3 control subject lines per cohort). (c) Representative tracings showing the dose-dependent effect of nicorandil on control, LQT, HCM, and DCM hiPSC-CM APs (Baseline: black, 10 nM: red, 100 nM: blue, 1 μM: purple, 10 μM: magenta). Dose-dependent shortening of the AP was observed in all groups (n=18, 3 patient or control subject lines per cohort). (d) Dose-response relationships showing shortening of the steady-state APD₉₀ by nicorandil on control, LQT, HCM, and DCM hiPSC-CMs. Data were fit by the Hill function (n=18, 3 patient or control subject lines per cohort). (e) IC₅₀ values of APD₉₀ shortening induced by nicorandil on control, LQT, HCM, and DCM hiPSC-CMs (n=18, 3 patient or control subject lines per cohort). Dashed lines show 0 mV. * indicates P<0.05, ** indicates P<0.01.
<table>
<thead>
<tr>
<th></th>
<th>hESCs</th>
<th>Control hiPSCs</th>
<th>LQT hiPSCs</th>
<th>HCM hiPSCs</th>
<th>DCM hiPSCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT4/TRA1-60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOX2/TRA1-81</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NANOG/SSEA4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1
### Figure 1, cont'd

<table>
<thead>
<tr>
<th>hESC-CMs</th>
<th>Control hiPSC-CMs</th>
<th>LQT hiPSC-CMs</th>
<th>HCM hiPSC-CMs</th>
<th>DCM hiPSC-CMs</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.jpg" alt="Image" /></td>
<td><img src="image2.jpg" alt="Image" /></td>
<td><img src="image3.jpg" alt="Image" /></td>
<td><img src="image4.jpg" alt="Image" /></td>
<td><img src="image5.jpg" alt="Image" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>αACTININ/DAPI</th>
<th>TNNT2/DAPI</th>
<th>MLC2v/MLC2a/DAPI</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image6.jpg" alt="Image" /></td>
<td><img src="image7.jpg" alt="Image" /></td>
<td><img src="image8.jpg" alt="Image" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Isotype control</th>
<th>hESC-CM</th>
<th>Isotype control</th>
<th>Control hiPSC-CM</th>
<th>Isotype control</th>
<th>LQT-CM</th>
<th>Isotype control</th>
<th>HCM-CM</th>
<th>Isotype control</th>
<th>DCM-CM</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image9.jpg" alt="Image" /></td>
<td><img src="image10.jpg" alt="Image" /></td>
<td><img src="image11.jpg" alt="Image" /></td>
<td><img src="image12.jpg" alt="Image" /></td>
<td><img src="image13.jpg" alt="Image" /></td>
<td><img src="image14.jpg" alt="Image" /></td>
<td><img src="image15.jpg" alt="Image" /></td>
<td><img src="image16.jpg" alt="Image" /></td>
<td><img src="image17.jpg" alt="Image" /></td>
<td><img src="image18.jpg" alt="Image" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>% of Max</th>
<th>100</th>
<th>80</th>
<th>60</th>
<th>40</th>
<th>20</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>10^0</td>
<td>10^1</td>
<td>10^2</td>
<td>10^3</td>
<td>10^4</td>
<td>10^5</td>
<td>10^6</td>
</tr>
</tbody>
</table>

**Figure 1, cont'd**
Figure 2
Figure 2, cont'd

b

Cell size by pixels

hESC-CMs  LQT hiPSC-CMs  HCM hiPSC-CMs  DCM hiPSC-CMs

Cotrol hiPSC-CMs

LQT hiPSC-CMs

HCM hiPSC-CMs

DCM hiPSC-CMs

% Cells with disorganized sarcomere

hESC-CMs  LQT hiPSC-CMs  HCM hiPSC-CMs  DCM hiPSC-CMs

Cotrol hiPSC-CMs

LQT hiPSC-CMs

HCM hiPSC-CMs

DCM hiPSC-CMs
<table>
<thead>
<tr>
<th>hESC-CMs</th>
<th>Control hiPSC-CMs</th>
<th>LQT hiPSC-CMs</th>
<th>HCM hiPSC-CMs</th>
<th>DCM hiPSC-CMs</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANF/TNNT2/DAPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2, cont’d
Figure 2, cont’d
Figure 2, cont’d
Figure 4
Figure 4, cont’d
**Figure 5**

- **a** hERG blockade assay, Verapamil
  
  ![Graph showing hERG blockade assay](image)

- **b** Normalized peak current vs. dose (μM)
  
  ![Graph showing normalized peak current](image)

- **c** hiPSC-CM/AP assay, Verapamil
  
  ![Graph showing hiPSC-CM/AP assay](image)

- **d** Normalized APD90 vs. dose (μM)
  
  ![Graph showing normalized APD90](image)
IC$_{50}$ = 2.12 ± 0.93 μM

IC$_{50}$ = 11.34 ± 0.72 μM
Figure 6
Figure 7

(a) LQT hiPSC-CMs

Baseline (without EADs)

100 nM nicorandil

10 μM nicorandil

Baseline (with EADs)

100 nM nicorandil

10 μM nicorandil

(b) Control hiPSC-CMs

Baseline

100 nM nicorandil

10 μM nicorandil
Figure 7, cont’d
Drug Screening Using a Library of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Disease Specific Patterns of Cardiotoxicity
Ping Liang, Feng Lan, Andrew S. Lee, Tingyu Gong, Veronica Sanchez-Freire, Yongming Wang, Sebastian Diecke, Karim Sallam, Joshua W. Knowles, Patricia K. Nguyen, Paul J. Wang, Donald M. Bers, Robert C. Robbins and Joseph C. Wu

Circulation. published online March 21, 2013;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2013/03/20/CIRCULATIONAHA.113.001883

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2013/03/21/CIRCULATIONAHA.113.001883.DC1.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/

Downloaded from http://circ.ahajournals.org/ by guest on May 1, 2016
SUPPLEMENTAL METHODS

Derivation of patient and disease-specific hiPSCs. Patient-specific hiPSCs were generated from dermal fibroblasts as previously reported using lentivirus on Matrigel-coated tissue culture dishes (BD Biosciences, San Jose, CA) with mTESR-1 hESC Growth Medium (STEMCELL Technologies, Vancouver, Canada).  

HEK293 cell culture. HEK293 cells stably expressing hERG were grown in Minimum Essential Medium (MEM) supplemented with 10% heat inactivated FBS, non-essential amino acids (1×), Sodium Pyruvate (1×), Penicillin-Streptomycin (100 U/ml and 100 U/ml), and G418 (500 µg/ml) (Gibco). In preparation for electrophysiological recordings, cells were trypsinized, washed in standard MEM media, and plated onto coverslips 1-2 days before recordings.  

Dissociation of beating EBs into single hESC-CMs and hiPSC-CMs for electrophysiological recordings. Dissociation of beating EBs was conducted as previously described. Briefly, spontaneously contracting EBs were mechanically collected, enzymatically dispersed into single cells and attached to Matrigel-coated glass coverslips (CS-22/40, Warner, Hamden, CT). 5-10 days after plating, stably contracting single hESC-CMs/hiPSC-CMs were subjected to patch clumping as described below.  

Quantitative real-time PCR. Total mRNAs were isolated from hESC-CMs, control iPSC-CMs, disease-specific hiPSC-CMs, HEK293 cells stably expressing hERG (hERG-HEK293),
blank HEK293, and human left ventricular tissue (LV) using the Qiagen RNeasy Mini kit. 1 
µg of RNA was used to synthesize cDNA using the SuperScript III First-Strand cDNA 
synthesis kit (Invitrogen). 0.25 µL of the reaction was used to quantify gene expression by 
quPCR using TaqMan Universal PCR Master Mix. Expression values were normalized to the 
average expression of housekeeping gene GAPDH.

**Teratoma formation.** 1x10⁶ undifferentiated hiPSCs were suspended in 10 µl Matrigel (BD 
Biosciences) and delivered by a 28.5 gauge syringe to the renal capsule of 8 week old SCID 
Beige mice. Eight weeks after cell delivery, tumors were explanted for hematoxylin and eosin 
(H&E) staining.

**Immunofluorescence staining.** Immunofluorescence was performed using appropriate 
primary antibodies and AlexaFluor conjugated secondary antibodies (Invitrogen) as 
previously described. The primary antibodies used in this study were Tra-1-60, Tra-1-81, 
SSEA-4, Oct 4, Nanog (Santa Cruz, CA), Sox2 (Biolegend, San Diego, CA), sarcomeric α-
actinin (Sigma, St. Louis, MO), cTnT (Thermo Scientific Barrington, IL), Myosin light chain 
2a (MLC2a), and Myosin light chain 2v (MLC2v) (Synaptic Systems, Goettingen, Germany).

**Electrophysiological recordings of HEK293 cells.** Traditional whole-cell voltage-clamp 
recording was performed at room temperature to record the hERG currents in HEK293 cells 
with an EPC-10 amplifier (HEKA, Germany). The pipette solution contained 130 mM KCl, 1 
mM MgCl₂, 10 mM HEPES, 5 mM Mg-ATP, 5 mM EGTA (pH 7.25 with KOH at 25°C); the
external solution contains 137 mM NaCl, 4 mM KCl, 1 mM MgCl₂, 10 mM glucose, 1.8 mM CaCl₂, and 10 mM HEPES (pH 7.4 with NaOH at 25°C). Capacitance and 60–80% series resistance were routinely compensated. The cells were voltage clamped at a holding potential of -80 mV. The hERG current was activated by depolarizing at +20 mV for 2 sec, after which the current was taken back to -50 mV for 2 sec to remove the inactivation and observe deactivation of the tail current. The first step at -50 mV was used as a baseline for measuring the tail current peak amplitude. After achieving whole-cell configuration, the cells were monitored for 90 sec to assess stability and washed with external solution for 60 sec. The voltage protocol described above was then applied to the cells every 20 sec throughout the whole procedure. Only stable cells with recording parameters above threshold were allowed to enter the drug treatment phase. External solution containing 0.1% DMSO (vehicle) was applied to cells to establish the baseline. After allowing the current to stabilize for 3 min, single cells were treated with drug compound solution as defined in the Methods section of the manuscript. Recordings of hERG current were maintained until the compound’s effect reached a steady state or for a maximum of 6 min. Washout with external solution was performed until the recovery of the current reached a steady state.

**Electrophysiological recordings of hESC-CMs and hiPSC-CMs.** To record spontaneous action potential recordings from hESC-CMs and hiPSC-CMs, a Giga-Ohm seal was achieved under the voltage-clamp mode and the APs were collected under the current-clamp configuration using an EPC-10 amplifier (HEKA, Germany). Contracting embryoid bodies (EBs) were mechanically isolated, enzymatically dispersed into single cells and attached to
0.1% gelatin-coated glass coverslips (Warner Instruments, CS-8R, USA). While recordings, the coverslips containing plated cardiomyocytes were transferred to a RC-26C recording chamber (Warner, USA) mounted on to the stage of an inverted microscope (Nikon, Tis, Japan). The glass pipettes were prepared using thin-wall borosilicate glass (A-M System, Catalog # 617000, USA) using a micropipette puller (Sutter Instrument, P-97, USA), polished using a microforge (Narishige, MF830, Japan) and had resistances between 2-4 MΩ. Extracellular solution perfusion was continuous using a rapid solution exchanger (Biologic, RC-200, USA) with solution exchange requiring ~1 min. Temperature was maintained constantly by a TC-324B heating system (Warner, USA) at 36 - 37 °C. Data were acquired using PatchMaster software (HEKA, Germany), digitized at 1.0 kHz and were analyzed using PulseFit (HEKA, Germany), Igor Pro (Wave Metrics), Microcal Origin 6.1 (OriginLab), or Prism 5 (GraphPad). The recordings were conducted in normal Tyrode solution containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM glucose, 1.8 mM CaCl2, and 10 mM HEPES (pH 7.4 with NaOH at 25°C). The pipette solution contained 120 mM KCl, 1 mM MgCl2, 10 mM HEPES, 3 mM Mg-ATP, and 10 mM EGTA (pH 7.2 with KOH at 25°C). For recordings on differentiated ventricular-like cardiomyocytes, the maximum diastolic potential (MDP) of single cardiomyocytes varied from −70 mV to −50 mV, action potential amplitude (APA) was greater than 90 mV, and action potential duration (APD)90/50 was less than 1.20. Only those cardiomyocytes satisfying the above criteria were considered to be ventricular-like cardiomyocytes and selected for drug screening. Escalating doses were sequentially applied to isolated single hESC-CMs and hiPSC-CMs. Steady-state was obtained for 3 min before application of higher doses. The average responses of 20 APs were analyzed.
for each dose. The steady-state before and after application were used to calculate the percentage of APD$_{90}$ prolongation/shortening at each dose. Dose-response data were fit to Hill equation. IC$_{50}$ here is defined the half maximal inhibitory concentration to block the hERG peak tail current or significantly prolong the APD$_{90}$. Significant APD$_{90}$ prolongation is defined as a $>10\%$ change in APD$_{90}$ at the indicated concentration $^4$. 
SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. Sequence analysis of patient-specific LQT, HCM, and DCM hiPSCs for KCNQ1, MYH7, and TNNT mutant loci. (a) Schematic pedigrees of the LQT, HCM and DCM families used in this study. Squares represent male family members and circles represent female family members. Solid and open symbols indicate presence and absence of the familial LQT, HCM, and DCM mutations, respectively. For the LQT cohort, hiPSCs were derived from three patients carrying the G269S mutation in KCNQ1 (II-1, II-2, and III-1) and one family-matched healthy individual (II-3). For the HCM cohort, hiPSCs were derived from three patients carrying the R663H mutation in MYH7 (I-1, II-1, and II-3) and one family matched control (II-2). For the DCM cohort, hiPSCs were derived from three patients carrying the R173W mutation in TNNT2 (I-1, I-2, and II-1) and one family-matched control (II-2). (b) Confirmation of the G269S missense mutation on exon 6 of the KCNQ1 gene in LQT patients (3 patient lines) by PCR and sequence analysis. (c) Confirmation of the R663H missense mutation on exon 18 of the MYH7 gene in HCM patients (3 patient lines) by PCR and sequence analysis. (d) Confirmation of the R173W missense mutation on exon 12 of the TNNT gene in DCM patients (3 patient lines) by PCR and sequence analysis.

Supplemental Figure 2. Transgene silencing in patient-specific hiPSCs. Quantitative PCR ratios for total versus endogenous expression of the reprogramming factors OCT4, SOX2, MYC and KLF4 in hESCs, control hiPSCs, LQT hiPSCs, HCM hiPSCs, and DCM hiPSCs.

Supplemental Figure 3. Pluripotency of patient-specific hiPSCs as demonstrated by teratoma formation. Representative H&E staining of a solid teratoma transplanted under the
renal capsule of an immunodeficient mouse show presence of cellular derivatives belonging to 3 germ layers including brain (ectoderm), skeletal muscle (mesoderm), and gut epithelium (endoderm).

Supplemental Figure 4. Cardiac differentiation efficiencies of patient-specific hiPSC lines. (a) Cardiac differentiation efficiency of control, LQT, HCM, and DCM hiPSC-CMs was measured by the % of beating EBs (n=50 per line, 3 lines per cohort). (b) Quantification of TNNT2-positive cardiomyocytes derived from control, LQT, HCM, and DCM hiPSC lines (n=50 per line, 3 lines per cohort).

Supplemental Figure 5. Capacitance measurements for patient-specific hiPSC-CM lines. Quantification of capacitance values for single hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs by patch clamp recordings (n=45-60, 3 lines per cohort). ** indicates P<0.01, as compared to control hiPSC-CMs.

Supplemental Figure 6. Electrophysiological profiling of disease-specific hiPSC-CMs. (a) Quantification of nodal-like, atrial-like, and ventricular-like APD_{90}/APD_{50} in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs. (b) Quantification of nodal-like, atrial-like, and ventricular-like V_{max} in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs. Please note the smaller V_{max} values for nodal-like cardiomyocytes. (c) Quantification of nodal-like, atrial-like, and ventricular-like MDP in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM
hiPSC-CMs, and DCM hiPSC-CMs. (d) Quantification of nodal-like, atrial-like, and ventricular-like overshoot in hESC-CMs, control hiPSC-CMs, LQT hiPSC-CMs, HCM hiPSC-CMs, and DCM hiPSC-CMs.

Supplemental Figure 7. Inter-comparison of electrophysiological baselines for family-matched control hiPSC-CMs belonging to LQT, HCM, and DCM cohorts. (a-c) APD_{50}, APD_{70}, and APD_{90} for each of the three myocyte subtypes (nodal-, atrial- and ventricular-like) in control hiPSC-CMs derived from healthy individuals belonging to LQT, HCM and DCM family cohorts. (d) Percentage of DADs and EADs observed in control hiPSC-CM lines derived from healthy individuals belonging to LQT, HCM and DCM family cohorts.

Supplemental Figure 8. Stability of HEK293 hERG tail currents. Peak tail currents were measured for a representative HEK-293 cell expressing hERG. Treatment with 0.1% DMSO (vehicle control) had no effect on hERG tail currents over an observation period of 8,000 seconds (n=3). The arrowhead indicates the time point at which 0.1% DMSO added.

Supplemental Figure 9. Comparison of APD_{90}-dose relationship between hESC-CMs and control hiPSC-CMs for verapamil and alfuzosin. (a) Upper panel: dose-response relationship of the steady-state APD_{90} prolongation for hESC-CMs and control hiPSC-CMs following treatment with verapamil. Data were fit by the Hill function. Lower panel: IC_{50} values of APD_{90} prolongation for hESC-CMs and control hiPSC-CMs following treatment with verapamil (n=9, 3 lines). (b) Upper panel: dose-response relationship of the steady-state
APD̄₉₀ for hESC-CMs and control hiPSC-CMs following treatment with alfuzosin. Data were fit by the Hill function. Lower panel: IC₅₀ values of APD₉₀ prolongation for hESC-CMs and control hiPSC-CMs following treatment with alfuzosin (n=9, 3 lines).

Supplemental Figure 10. Electrophysiological stability of hiPSC-CM APs during vehicle treatment. Control hiPSC-CMs were treated with 0.1% DMSO (vehicle control) for 10 minutes. Representative traces are shown at time 0, 1 minute, 2 minutes, 5 minutes, 8 minutes, and 10 minutes (black, red, blue, purple, magenta and cyan, respectively) (n=6, 3 lines).

Supplemental Figure 11. Concentration-dependent block of hERG by cisapride in hERG expressing HEK293 cells. (a) Representative time course for treatment of a hERG expressing HEK293 cell at the following concentrations of cisapride: 1 nM, 10 nM, 30 nM, 100 nM, 300 nM, and 1 µM. (b) Representative traces showing the effect of cisapride on blockade of hERG current at doses of 0 nM, 1 nM, 10 nM, 30 nM, 100 nM, 300 nM, and 1 µM (black, red, blue, purple, magenta, cyan and green traces, respectively). Dose-dependent inhibition of hERG current was clearly observed. (c) Dose-response relationship showing steady-state inhibition of hERG by cisapride. IC₅₀ was calculated by fitting a Hill function to the data constrained to 100% inhibition. IC₅₀ for cisapride was 0.032 ± 0.003 µM (n=5 for each dose).
Supplemental Figure 12. Inter-comparison of cisapride and nicorandil-induced cardiotoxicity for family-matched control hiPSC-CMs belonging to LQT, HCM, and DCM cohorts. (a) Dose-response relationship showing steady-state prolongation of APD$_{90}$ by cisapride for family-matched control hiPSC-CM lines derived from healthy subjects belonging to LQT, HCM and DCM cohorts. (b) IC$_{50}$ values of APD$_{90}$ prolongation of cisapride for control hiPSC-CM lines derived from LQT, HCM and DCM family cohorts. (c) Dose-response relationship showing steady-state shortening of APD$_{90}$ by nicorandil for control hiPSC-CMs derived from LQT, HCM and DCM family cohorts. (d) IC$_{50}$ values of nicorandil-induced APD$_{90}$ shortening for control hiPSC-CM lines derived from LQT, HCM, and DCM family cohorts.

Supplemental Figure 13. Schematic for personalized approach to determination of drug-induced cardiotoxicity. Patient-specific somatic cells are reprogrammed to pluripotency by defined factors, differentiated to cardiac lineages and screened for drug response. Dosages and patient-specific toxicities can be calibrated based upon *in vitro* readouts of cardiotoxicity such as APD prolongation or induction of EADs/DADs at the single cell level.

Supplemental Video 1. Representative video of beating EBs generated by cardiac differentiation in suspension.

Supplemental Video 2. Representative video of the contracting cardiomyocytes dissociated from beating EBs.
SUPPLEMENTAL REFERENCES


Supplemental Figure 1

LQT family
KCNQ1, G269S

HCM family
MYH7, R663H

DCM family
TNNT2, R173W
Supplemental Figure 1

b. LQT KCNQ1 G269S G-A

c. HCM MYH7 R663H G-A

d. DCM TNNT2 R173W C-T
Supplemental Figure 2
Supplemental Figure 3

Neural element (Ectodermal)

Skeletal muscle (Mesodermal)

Gut epithelium (Endodermal)
Supplemental Figure 4
Supplemental Figure 5
Supplemental Figure 6
Supplemental Figure 7

(a) Nodal-like APDs (ms)

(b) Atrial-like APDs (ms)

(c) Ventricular-like APDs (ms)

(d) Percentage of cells showing EADs and DADs
Vehicle Stability of hERG assay

Supplemental Figure 8
Supplemental Figure 9

(a) Verapamil

(b) Alfuzosin

Prolongation of APD

Normalized APD_{90}

Dose (µM)

hESC-CMs
Control hiPSC-CMs

IC_{50} (µM)

Prolongation of APD_{90}

hESC-CMs
Control hiPSC-CMs
Vehicle Stability of AP/hiPSC-CM assay

Supplemental Figure 10
Supplemental Figure 11
Supplemental Figure 12

(a) Normalized APD$_{90}$ vs Dose (µM) for LQT family-matched control, HCM family-matched control, and DCM family-matched control.

(b) IC$_{50}$ of Cisapride (µM) for APD$_{90}$ prolongation.

(c) Normalized APD$_{90}$ vs Dose (µM) for LQT family-matched control, HCM family-matched control, and DCM family-matched control.

(d) IC$_{50}$ of Nicorandil (µM) for APD$_{90}$ shortening.
Supplemental Figure 13
Supplemental Table 1. Panel of hiPSCs from cardiovascular disease-specific patients and healthy controls for drug screening

<table>
<thead>
<tr>
<th></th>
<th>Genetic cause</th>
<th>Number of clones/patient-specific lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human ESCs (H9)</td>
<td>None</td>
<td>1</td>
</tr>
<tr>
<td>Control hiPSCs</td>
<td>None</td>
<td>3</td>
</tr>
<tr>
<td>LQT hiPSCs</td>
<td>KCNQ1 G269S</td>
<td>3</td>
</tr>
<tr>
<td>HCM hiPSCs</td>
<td>MYH7 R663H</td>
<td>3</td>
</tr>
<tr>
<td>DCM hiPSCs</td>
<td>TNNT2 R173W</td>
<td>3</td>
</tr>
</tbody>
</table>
### Supplemental Table 2. Panel of LQT, HCM and DCM genes for genetic screening

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Protein Coded</th>
<th>NCBI Ref Gene No.</th>
<th>H9 Control</th>
<th>LQT</th>
<th>HCM</th>
<th>DCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTC1</td>
<td>alpha-cardiac actin</td>
<td>NG_007553</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>CAV3</td>
<td>caveolin 3</td>
<td>NG_008797</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>GLA</td>
<td>galactosidase alpha</td>
<td>NG_007119</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>LAMP2</td>
<td>lysosomal-associated membrane protein 2</td>
<td>NG_007995</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTG</td>
<td>mitochondrial transfer RNA glycine</td>
<td>NC_012920_TRNG</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTI</td>
<td>mitochondrial transfer RNA isoleucine</td>
<td>NC_012920_TRNI</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTK</td>
<td>mitochondrial transfer RNA lysine</td>
<td>NC_012920_TRNK</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTQ</td>
<td>mitochondrial transfer RNA glutamine</td>
<td>NC_012920_TRNQ</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MYBPC3</td>
<td>cardiac myosin-binding protein C</td>
<td>NG_007667</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MYH7</td>
<td>beta-myosin heavy chain</td>
<td>NG_007884</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MYL2</td>
<td>myosin regulatory light chain 2</td>
<td>NG_007554</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MYL3</td>
<td>myosin light chain 3</td>
<td>NG_007555</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>PRKAG2</td>
<td>5'-AMP-activated protein kinase subunit gamma-2</td>
<td>NG_007486</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TNNC1</td>
<td>troponin C</td>
<td>NG_008963</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TNNI3</td>
<td>cardiac muscle troponin I</td>
<td>NG_007866</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TNNT2</td>
<td>cardiac muscle troponin T</td>
<td>NG_007556</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TPM1</td>
<td>alpha tropomyosin</td>
<td>NG_007553</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TTR</td>
<td>transthyretin</td>
<td>NG_009490</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>LMNA</td>
<td>lamin A/C</td>
<td>NG_008692</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>DES</td>
<td>desmin</td>
<td>NG_008043</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>LDB3</td>
<td>LIM domain binding 3 (ZASP)</td>
<td>NG_008876</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>TAZ</td>
<td>tafazzin</td>
<td>NG_009634</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>PLN</td>
<td>phospholamban</td>
<td>NG_009082</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Bolded mutations indicate known disease-causing variants.*
<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Description</th>
<th>Accession</th>
<th>Exon 1</th>
<th>Exon 2</th>
<th>Exon 3</th>
<th>Exon 4</th>
<th>Exon 5</th>
<th>Exon 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTR</td>
<td>transthyretin</td>
<td>NG_009490</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>LAMP2</td>
<td>lysosomal-associated membrane protein 2</td>
<td>NG_007995</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>SGCD</td>
<td>delta sarcoglycan</td>
<td>NG_008693</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTL1</td>
<td>mitochondrially encoded tRNAleucine 1</td>
<td>NC_012920_TRNL1</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTQ</td>
<td>mitochondrially encoded tRNA glutamine</td>
<td>NC_012920_TRNQ</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTH</td>
<td>mitochondrially encoded tRNA histidine</td>
<td>NC_012920_TRNH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTK</td>
<td>mitochondrially encoded tRNA lysine</td>
<td>NC_012920_TRNK</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTS1</td>
<td>mitochondrially encoded tRNA serine 1</td>
<td>NC_012920_TRNS1</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTTS2</td>
<td>mitochondrially encoded tRNA serine 1</td>
<td>NC_012920_TRNS2</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTND1</td>
<td>mitochondrially encoded NADH dehydrogenase 1</td>
<td>NC_012920_ND1</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTND5</td>
<td>mitochondrially encoded NADH dehydrogenase 5</td>
<td>NC_012920_ND5</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>MTND6</td>
<td>mitochondrially encoded NADH dehydrogenase 6</td>
<td>NC_012920_ND6</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNQ1</td>
<td>potassium voltage-gated channel, KQT-like subfamily, member 1</td>
<td>NC_000011.9</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNH2</td>
<td>potassium voltage-gated channel, subfamily H (eag-related), member 2</td>
<td>NC_000007.13</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>SCN5A</td>
<td>sodium channel, voltage-gated, type V, alpha subunit</td>
<td>NC_000003.11</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>ANK2</td>
<td>ankyrin 2, neuronal</td>
<td>NC_000004.11</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNE1</td>
<td>potassium voltage-gated channel, Isk-related family, member 1</td>
<td>NC_000021.8</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNE2</td>
<td>potassium voltage-gated channel, Isk-related family, member 2</td>
<td>NC_000021.8</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNJ2</td>
<td>potassium inwardly-rectifying channel, subfamily J, member 2</td>
<td>NC_000017.10</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>CACNA1C</td>
<td>calcium channel, voltage-dependent, L type, alpha 1C subunit</td>
<td>NC_000012.11</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>CAV3</td>
<td>caveolin 3</td>
<td>NC_000003.11</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>SCN4B</td>
<td>sodium channel, voltage-gated, type IV, beta subunit</td>
<td>NC_000011.9</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>AKAP9</td>
<td>A kinase (PRKA) anchor protein (yotiao) 9</td>
<td>NC_000007.13</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>SNTA1</td>
<td>syntrophin, alpha 1</td>
<td>NC_000020.10</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>KCNJ5</td>
<td>potassium inwardly-rectifying channel, subfamily J, member 5</td>
<td>NC_000011.9</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
### Supplemental Table 3. Panel of cardiac ion channel-related transcripts used for quantitative RT-PCR

<table>
<thead>
<tr>
<th></th>
<th>Gene</th>
<th>ASSAY ID</th>
<th>Gene description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GADPH</td>
<td>Hs99999905_m1</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>2</td>
<td>SCN5A</td>
<td>Hs00165693_m1</td>
<td>Nav1.5</td>
</tr>
<tr>
<td>3</td>
<td>KCND3</td>
<td>Hs00542597_m1</td>
<td>Kv4.3 (I&lt;sub&gt;I&lt;/sub&gt;)</td>
</tr>
<tr>
<td>4</td>
<td>CACNA1C</td>
<td>Hs00167681_m1</td>
<td>Ca&lt;sub&gt;I&lt;/sub&gt;</td>
</tr>
<tr>
<td>5</td>
<td>KCNH2</td>
<td>Hs04234270_g1</td>
<td>Kv11.1 (hERG/I&lt;sub&gt;kr&lt;/sub&gt;)</td>
</tr>
<tr>
<td>6</td>
<td>KCNQ1</td>
<td>Hs00923522_m1</td>
<td>Kv7.1, α-subunit of I&lt;sub&gt;ks&lt;/sub&gt;</td>
</tr>
<tr>
<td>7</td>
<td>KCNA5</td>
<td>Hs00266898_s1</td>
<td>Kv1.5</td>
</tr>
<tr>
<td>8</td>
<td>HCN2</td>
<td>Hs00606903_m1</td>
<td>Hyperpolarization-activated cyclic nucleotide-gated channel (I&lt;sub&gt;I&lt;/sub&gt;)</td>
</tr>
<tr>
<td>9</td>
<td>HCN4</td>
<td>Hs00175760_m1</td>
<td>Hyperpolarization-activated cyclic nucleotide-gated channel (I&lt;sub&gt;I&lt;/sub&gt;)</td>
</tr>
<tr>
<td>10</td>
<td>KCNJ2</td>
<td>Hs00265315_m1</td>
<td>Inward rectifier K&lt;sup&gt;+&lt;/sup&gt; channel Kir2.1</td>
</tr>
<tr>
<td>11</td>
<td>KCNJ3</td>
<td>Hs01002552_m1</td>
<td>Inward rectifier K&lt;sup&gt;+&lt;/sup&gt; channel Kir3.1</td>
</tr>
<tr>
<td>12</td>
<td>KCNJ5</td>
<td>Hs00942581_m1</td>
<td>Inward rectifier K&lt;sup&gt;+&lt;/sup&gt; channel Kir3.4</td>
</tr>
<tr>
<td>13</td>
<td>KCNJ11</td>
<td>02625248_s1</td>
<td>ATP-sensitive inward rectifier K&lt;sup&gt;+&lt;/sup&gt; channelKir6.2</td>
</tr>
<tr>
<td>14</td>
<td>KCNE1</td>
<td>Hs00897540_s1</td>
<td>minK, β-subunit of I&lt;sub&gt;ks&lt;/sub&gt;</td>
</tr>
<tr>
<td>15</td>
<td>KChIP2</td>
<td>Hs01552688_g1</td>
<td>β-subunit of I&lt;sub&gt;io&lt;/sub&gt;</td>
</tr>
</tbody>
</table>
Supplemental Table 4. Summary of action potential parameters in hESC-CMs and hiPSC-CMs

<table>
<thead>
<tr>
<th></th>
<th>% of cells</th>
<th>Beating rate (bpm)</th>
<th>MDP (mV)</th>
<th>Overshoot (mV)</th>
<th>APA (mV)</th>
<th>APD&lt;sub&gt;50&lt;/sub&gt; (ms)</th>
<th>APD&lt;sub&gt;70&lt;/sub&gt; (ms)</th>
<th>APD&lt;sub&gt;90&lt;/sub&gt; (ms)</th>
<th>V&lt;sub&gt;max&lt;/sub&gt; (V/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>hESC-CMs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal-like</td>
<td>5</td>
<td>97 ± 12</td>
<td>-38.7 ± 2.8</td>
<td>32.4 ± 0.7</td>
<td>71.2 ± 1.7</td>
<td>142.5 ± 12.3</td>
<td>190.3 ± 16.7</td>
<td>242.7 ± 24.6</td>
<td>3.3 ± 0.6</td>
</tr>
<tr>
<td>Atrial-like</td>
<td>27</td>
<td>68 ± 5</td>
<td>-53.3 ± 1.0</td>
<td>45.6 ± 1.2</td>
<td>97.3 ± 1.3</td>
<td>178.6 ± 10.0</td>
<td>231.0 ± 10.4</td>
<td>298.5 ± 33.8</td>
<td>33.5 ± 8.7</td>
</tr>
<tr>
<td>Ventricular-like</td>
<td>68</td>
<td>48 ± 5</td>
<td>-57.2 ± 1.3</td>
<td>46.2 ± 2.3</td>
<td>101.1 ± 1.3</td>
<td>310.0 ± 14.2</td>
<td>320.6 ± 20.3</td>
<td>340.8 ± 38.7</td>
<td>25.1 ± 9.1</td>
</tr>
<tr>
<td><strong>Normal hiPSC-CMs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal-like</td>
<td>8</td>
<td>75 ± 8</td>
<td>-34.3 ± 3.5</td>
<td>30.6 ± 1.1</td>
<td>65.1 ± 0.9</td>
<td>104.4 ± 20.2</td>
<td>204.7 ± 12.5</td>
<td>288.1 ± 25.5</td>
<td>3.4 ± 0.8</td>
</tr>
<tr>
<td>Atrial-like</td>
<td>29</td>
<td>48 ± 7</td>
<td>-47.2 ± 1.3</td>
<td>44.3 ± 1.8</td>
<td>90.7 ± 2.9</td>
<td>172.2 ± 12.3</td>
<td>220.4 ± 22.8</td>
<td>293.6 ± 20.3</td>
<td>28.9 ± 7.3</td>
</tr>
<tr>
<td>Ventricular-like</td>
<td>63</td>
<td>54 ± 9</td>
<td>-52.6 ± 0.7</td>
<td>46.0 ± 1.0</td>
<td>97.2 ± 1.3</td>
<td>326.4 ± 26.9</td>
<td>340.5 ± 14.6</td>
<td>370.2 ± 32.4</td>
<td>27.7 ± 5.3</td>
</tr>
<tr>
<td><strong>LQT hiPSC-CMs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal-like</td>
<td>7</td>
<td>101 ± 11</td>
<td>-42.1 ± 1.7</td>
<td>29.9 ± 2.1</td>
<td>73.7 ± 4.1</td>
<td>187.6 ± 12.8</td>
<td>231.5 ± 17.5</td>
<td>283.0 ± 24.7</td>
<td>3.1 ± 0.4</td>
</tr>
<tr>
<td>Atrial-like</td>
<td>33</td>
<td>80 ± 9</td>
<td>-54.1 ± 1.3</td>
<td>48.4 ± 1.5</td>
<td>102.7 ± 4.7</td>
<td>416.3 ± 30.7***</td>
<td>467.3 ± 30.5***</td>
<td>514.7 ± 28.5***</td>
<td>31.1 ± 6.6</td>
</tr>
<tr>
<td>Ventricular-like</td>
<td>60</td>
<td>58 ± 4</td>
<td>-59.3 ± 0.8</td>
<td>50.0 ± 1.1</td>
<td>109.3 ± 1.8</td>
<td>821.5 ± 47.2***</td>
<td>839.4 ± 50.2***</td>
<td>884.2 ± 48.2***</td>
<td>25.9 ± 5.0</td>
</tr>
<tr>
<td><strong>HCM hiPSC-CMs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal-like</td>
<td>5</td>
<td>82 ± 7</td>
<td>-31.9 ± 2.1</td>
<td>31.0 ± 2.2</td>
<td>61.6 ± 4.0</td>
<td>173.1 ± 21.2</td>
<td>213.8 ± 15.4</td>
<td>265.9 ± 25.5</td>
<td>2.1 ± 0.6</td>
</tr>
<tr>
<td>Atrial-like</td>
<td>28</td>
<td>63 ± 5</td>
<td>-52.7 ± 1.7</td>
<td>44.6 ± 1.1</td>
<td>97.5 ± 0.9</td>
<td>170.5 ± 11.8</td>
<td>217.7 ± 31.6</td>
<td>346.3 ± 40.5</td>
<td>30.4 ± 8.6</td>
</tr>
<tr>
<td>Ventricular-like</td>
<td>67</td>
<td>50 ± 2</td>
<td>-54.9 ± 0.7</td>
<td>48.8 ± 0.7</td>
<td>103.0 ± 1.0</td>
<td>374.5 ± 16.7</td>
<td>408.2 ± 21.5</td>
<td>426.1 ± 17.6</td>
<td>27.9 ± 7.9</td>
</tr>
<tr>
<td><strong>DCM hiPSC-CMs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodal-like</td>
<td>5</td>
<td>68 ± 15</td>
<td>-31.8 ± 2.3</td>
<td>30.7 ± 1.5</td>
<td>62.5 ± 1.4</td>
<td>169.6 ± 16.5</td>
<td>192.4 ± 21.8</td>
<td>240.8 ± 31.6</td>
<td>2.3 ± 1.1</td>
</tr>
<tr>
<td>Atrial-like</td>
<td>27</td>
<td>64 ± 11</td>
<td>-48.7 ± 3.7</td>
<td>42.5 ± 2.7</td>
<td>91.4 ± 2.2</td>
<td>176.2 ± 14.0</td>
<td>222.6 ± 25.4</td>
<td>278.8 ± 26.3</td>
<td>23.3 ± 8.1</td>
</tr>
<tr>
<td>Ventricular-like</td>
<td>68</td>
<td>59 ± 9</td>
<td>-54.8 ± 1.6</td>
<td>49.4 ± 1.1</td>
<td>104.2 ± 1.7</td>
<td>381.1 ± 30.2</td>
<td>415.5 ± 31.4</td>
<td>435.8 ± 35.4</td>
<td>23.4 ± 7.9</td>
</tr>
</tbody>
</table>
Supplemental Table 5. Summary of drug-induced hERG tail current inhibition on HEK293 cells

<table>
<thead>
<tr>
<th></th>
<th>Dose (µM)</th>
<th>Inhibition of hERG Current (Δ%)</th>
<th>IC₅₀ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisapride</td>
<td>0.001</td>
<td>8.0±4.0</td>
<td>0.032±0.003</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>25.0±3.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>50.0±5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>90.0±5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>97.7±3.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>99.2±8.0</td>
<td></td>
</tr>
<tr>
<td>Nicorandil</td>
<td>0.1</td>
<td>3.0±3.2</td>
<td>&gt;100</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>-5.4±4.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>6.2±6.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>10.7±5.4</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>0.01</td>
<td>4.4±1.0</td>
<td>0.194±0.050</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>37.7±3.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>55.0±5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>89.4±2.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>96.2±0.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>98.8±0.3</td>
<td></td>
</tr>
<tr>
<td>Alfuzosin</td>
<td>0.1</td>
<td>6.0±5.0</td>
<td>11.34±0.72</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>10.0±5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>16.0±7.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>47.0±10.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>92.0±0.6</td>
<td></td>
</tr>
</tbody>
</table>
### Supplemental Table 6. Summary of drug-induced effects on action potentials

<table>
<thead>
<tr>
<th>Drug</th>
<th>hESC-CMs (H9)</th>
<th>Control hiPSC-CMs</th>
<th>LQT hiPSC-CMs</th>
<th>HCM hiPSC-CMs</th>
<th>DCM hiPSC-CMs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose (µM)</td>
<td>APD&lt;sub&gt;90&lt;/sub&gt; (Δ%)</td>
<td>Dose (µM)</td>
<td>APD&lt;sub&gt;90&lt;/sub&gt; (Δ%)</td>
<td>Dose (µM)</td>
<td>APD&lt;sub&gt;90&lt;/sub&gt; (Δ%)</td>
</tr>
<tr>
<td>Cisapride</td>
<td>0.001</td>
<td>4.0±0.3</td>
<td>0.001</td>
<td>2.6±0.4</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>0.003</td>
<td>8.4±1.2</td>
<td>0.003</td>
<td>7.9±1.1</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>32.0±5.0</td>
<td>0.01</td>
<td>30.5±5.4</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>75.0±2.2</td>
<td>0.03</td>
<td>77.3±2.6</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>120.0±10.0</td>
<td>0.1</td>
<td>125.0±18.8</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>EAD</td>
<td>0.3</td>
<td>EAD</td>
<td>0.3</td>
</tr>
<tr>
<td>Nicorandil</td>
<td>0.001</td>
<td>-5.7±2.9</td>
<td>0.001</td>
<td>-5.7±2.9</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>-7.0±5.8</td>
<td>0.01</td>
<td>-7.0±5.8</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>-13.0±5.8</td>
<td>0.1</td>
<td>-10.0±5.8</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>-20.0±6.9</td>
<td>0.3</td>
<td>-17.0±6.9</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>-23.8±7.5</td>
<td>1</td>
<td>-25.0±7.5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>-51.7±11.5</td>
<td>10</td>
<td>-48.4±11.5</td>
<td>10</td>
</tr>
<tr>
<td>Verapamil</td>
<td>0.1</td>
<td>5.0±8.7</td>
<td>0.1</td>
<td>2.5±5.8</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>7.0±7.5</td>
<td>1</td>
<td>5.0±8.7</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>10.0±8.0</td>
<td>3</td>
<td>10.0±7.0</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>26.0±6.4</td>
<td>10</td>
<td>25.3±5.8</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>27.0±8.0</td>
<td>30</td>
<td>25.8±10.0</td>
<td>-</td>
</tr>
<tr>
<td>Alfuzosin</td>
<td>0.1</td>
<td>0.3±1.2</td>
<td>0.1</td>
<td>-1.4±4.6</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>3.2±4.1</td>
<td>0.3</td>
<td>4.1±5.2</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>14.2±6.7</td>
<td>1</td>
<td>18.9±5.8</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>22.9±5.3</td>
<td>3</td>
<td>25.8±6.9</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>26.8±9.4</td>
<td>10</td>
<td>27.2±8.7</td>
<td>-</td>
</tr>
</tbody>
</table>

Quantitative data are presented as mean ± s.e.m.. Comparison between the groups was performed by one-way analysis of variance (ANOVA), followed by the Dunnett test (for comparison of all groups to control hiPSC-CMs). * indicates P value of <0.05, ** indicates P value of <0.01.
**Supplemental Table 7. Panel of drugs used for drug screening on hESC-CMs and patient-specific hiPSC-CMs**

<table>
<thead>
<tr>
<th>Tested drugs</th>
<th>Phase target</th>
<th>Ion channel target</th>
<th>Current target</th>
<th><strong>IC₅₀ of hERG current inhibition (µM)</strong></th>
<th><strong>IC₅₀ of APD prolongation/shortening (µM)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Control hiPSC-CMs</td>
<td>LQT-CMs</td>
</tr>
<tr>
<td>Cisapride</td>
<td>2, 3</td>
<td>hERG blocker</td>
<td>Iₖr</td>
<td>0.032 ± 0.003</td>
<td>0.035 ± 0.004</td>
</tr>
<tr>
<td>Nicorandil</td>
<td>3</td>
<td>K-ATP channel opener</td>
<td>Iₖs</td>
<td>&gt;100</td>
<td>13.44 ± 2.1</td>
</tr>
<tr>
<td>Verapamil</td>
<td>2, 3</td>
<td>L-type Ca²⁺ channel blocker, hERG blocker</td>
<td>Iₖa</td>
<td>0.194 ± 0.05</td>
<td>5.18 ± 2.6</td>
</tr>
<tr>
<td>Alfuzosin</td>
<td>1</td>
<td>Sodium channel (Na,1.5) opener</td>
<td>Iₙa</td>
<td>11.34 ± 0.72</td>
<td>2.12 ± 0.93</td>
</tr>
</tbody>
</table>